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Deficiency in COG5 causes a moderate form of congenital
disorders of glycosylation
Abstract
The conserved oligomeric Golgi (COG) complex is a tethering factor composed of eight subunits that is
involved in the retrograde transport of intra-Golgi components. Deficient biosynthesis of COG subunits
leads to alterations of protein trafficking along the secretory pathway and thereby to severe diseases in
humans. Since the COG complex affects the localization of several Golgi glycosyltransferase enzymes,
COG deficiency also leads to defective protein glycosylation, thereby explaining the classification of
COG deficiencies as forms of congenital disorders of glycosylation (CDG). To date, mutations in
COG1, COG4, COG7 and COG8 genes have been associated with diseases, which range from severe
multi-organ disorders to moderate forms of neurological impairment. In the present study, we describe a
new type of COG deficiency related to a splicing mutation in the COG5 gene. Sequence analysis in the
patient identified a homozygous intronic substitution (c.1669-15T>C) leading to exon skipping and
severely reduced expression of the COG5 protein. This defect was associated with a mild psychomotor
retardation with delayed motor and language development. Analysis of different serum glycoproteins
revealed a CDG phenotype with typical undersialylation of N- and O-glycans. Retrograde
Golgi-to-endoplasmic reticulum trafficking was markedly delayed in the patient's fibroblast upon
brefeldin-A treatment, which is a hallmark of COG deficiency. This trafficking delay could be restored
to normal values by expressing a wild-type COG5 cDNA in the patient cells. This case demonstrates
that COG deficiency and thereby CDG must be taken into consideration even in children presenting
mild neurological impairments.
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ABSTRACT 
 
The conserved oligomeric Golgi (COG) complex is a tethering factor composed of eight 
subunits that is involved in the retrograde transport of intra-Golgi components. Deficient 
biosynthesis of COG subunits leads to alterations of protein trafficking along the secretory 
pathway and thereby to severe diseases in humans. Since the COG complex affects the 
localization of several Golgi glycosyltransferase enzymes, COG deficiency also leads to 
defective protein glycosylation, thereby explaining the classification of COG deficiencies as 
forms of congenital disorder of glycosylation (CDG). To date, mutations in COG1, COG4, 
COG7 and COG8 genes have been associated with diseases, which range from severe multi-
organ disorders to moderate forms of neurological impairment. In the present study, we 
describe a new type of COG deficiency related to a splicing mutation in the COG5 gene. 
Sequence analysis in the patient identified a homozygous intronic substitution (c.1669-
15T>C) leading to exon skipping and severely reduced expression of the COG5 protein. This 
defect was associated with a mild psychomotor retardation with delayed motor and language 
development. Analysis of different serum glycoproteins revealed a CDG phenotype with 
typical undersialylation of N- and O-glycans. Retrograde Golgi-to-endoplasmic reticulum 
trafficking was markedly delayed in the patient’s fibroblast upon brefeldin-A treatment, 
which is a hallmark of COG deficiency. This trafficking delay could be restored to normal 
values by expressing a wildtype COG5 cDNA in the patient cells. This case demonstrates that 
COG deficiency and thereby CDG must be taken into consideration even in children 
presenting mild neurological impairments. 
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INTRODUCTION 
Glycosylation is an ubiquitous form of post-translational modification that is essential in most 
living organisms. In humans, defects of glycosylation cause diseases classified under the 
generic name of congenital disorders of glycosylation (CDG). The features of these diseases 
reflect the broad physiological relevance of glycans, thereby ranging from multi-organ 
failures, dysmorphisms and skeletal malformations to hormonal disorders and coagulopathies 
(1-3). The clinical manifestations depend also on the type of glycosylation affected. Defects 
of N-glycosylation are rather associated with neurological disorders, whereas defects of O-
mannosylation are linked to congenital muscular dystrophies (4) and defects of mucin-type O-
glycosylation for example with anemia (5) and tumoral calcinosis (6). 
Diagnosis of CDG is usually reached by isoelectric focusing (IEF) of the serum proteins 
transferrin and apolipoprotein CIII (ApoCIII) (7) followed by specific enzymatic assays and 
mutation analysis (8, 9). Most forms of CDG can be assigned to mutations in genes 
participating in glycan biosynthesis including glycosyltransferases, glycosidases, sugar 
transporters and enzymes involved in the production of substrates for the glycosylation 
reactions. Only recently, defects in genes involved in vesicular trafficking have been shown to 
cause CDG. Mutations in the genes encoding subunits of the conserved oligomeric Golgi 
(COG) complex were the first group of CDG defects to be found outside of the glycosylation 
pathway (10-12). The COG complex has been described as a cytosolic protein complex that is 
peripherally associated with the Golgi serving as a tethering factor for retrograde vesicular 
transport. 
To date, mutations in genes encoding four of the COG subunits, namely COG1, COG4, 
COG7 and COG8, have been described as causing CDG (13-17). In COG-deficient cells, the 
intra-Golgi retrograde transport is disturbed, which affects the distribution of so-called GEAR 
proteins (18). The GEAR protein family includes SNARE proteins, the golgin and giantin 
matrix proteins and glycosyltransferases and glycosidases, such as -mannosidase II, 1,2-N-
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acetylglucosaminyltransferase I, -2,3-sialyltransferase I (13, 18, 19). Because of the 
abnormal distribution of several glycosylation enzymes, COG deficiency is usually associated 
with underglycosylation of proteins and thus with typical CDG phenotypes. Besides leading 
to glycosylation defects, COG deficient cells have previously been shown to respond slowly 
to brefeldin-A (BFA) treatment (20). This drug blocks the GDP/GTP-exchange factor of 
ADP-ribosylation factor 1 and inhibits the formation of COPI vesicles on the Golgi 
membrane. It leads to a rapid redistribution of Golgi proteins into the endoplasmic reticulum 
(ER) (21), a process that can be visualized by immunofluorescence microscopy of Golgi 
resident proteins. Considering the combined impairment of vesicular trafficking and protein 
glycosylation, it is expected that COG deficiency leads to severe diseases. However, as 
reported here, it appears that COG deficiency can also be associated with relatively mild 
clinical features.  
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RESULTS 
The index patient is the first child of remotely consanguineous parents of Iraqi origin. At her 
first neuropsychological examination at the age of 8 years, she showed global developmental 
delay with moderate mental retardation (IQ around 50-55). She showed no dysmorphic 
features, growth retardation or ocular motor apraxia. However, her speech was slow and 
inarticulate. She had a tendency to tumble and displayed truncal ataxia and slight muscular 
hypotonia and showed a slight coordination deficiency in the finger-nose test. Magnetic 
resonance imaging analysis showed pronounced diffuse atrophy of the cerebellum and brain 
stem (data not shown). The supratentorial brain parenchyma was without pathological 
findings. Karyotype analysis, routine laboratory tests, such as measurement of liver enzymes, 
alkaline phosphatase, lactate and ammonia in blood as well as organic and amino acids in 
urine were without pathological findings. Furthermore, screens for inborn errors of 
metabolism including thyreotropin-releasing-hormone, -fetoprotein, very-long-chain fatty 
acids and vitamin E were normal. At the age of 12, IEF of serum transferrin was performed, 
leading to the first indication for CDG (Fig. 1A). Now at 14 years, she has a good speech 
perception, even tough her speed of speech is still slow. Her language skills improved 
significantly and her education is bilingual (Arabic/German). She remains mildly hypotonic, 
with normal reflexes, good strength and truncal ataxia without extrapyramidal signs. Blood 
for genomic DNA analysis was drawn from all family members, whereas a skin biopsy was 
taken only from the index patient. 
The IEF of serum transferrin in the patient showed increased levels of trisialo-transferrin that 
clearly differed from the pattern of a control subject or a patient with a N-glycosylation defect 
caused by a phosphomannomutase2 (PMM2) deficiency (Fig. 1A). This accumulation of 
trisialo-transferrin is usually a sign of normal N-glycosylation site occupancy but incomplete 
N-glycan structures. To investigate the N-glycan structure, we have analyzed serum 
transferrin using electrospray ionization mass spectrometry (Fig. 1B). The observed 
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transferrin peaks were assigned according to the calculated molecular masses (22). In the 
patient sample, an elevated peak at 79'248 Da was observed. The mass shift of about 300 Da 
indicated the loss of a single sialic acid residue in the glycoprotein. This finding was 
compatible with the result obtained from the IEF analysis. 
Considering the modest underglycosylation of serum transferrin, we assessed additional 
serum glycoproteins such as haptoglobin and 1-acid glycoprotein (AGP). Haptoglobin 
normally carries four N-glycans (23), whereas haptoglobin from a PMM2-deficient patient 
shows underglycosylated protein forms missing complete N-glycans (Fig. 1C). However, 
haptoglobin from the present patient did not show any loss of N-glycans, although it appeared 
to migrate slightly faster in the SDS-PAGE compared to the control lane, suggesting truncated 
glycan structures on the protein of the patient (Fig. 1C).  Enzymatic release of N-glycans with 
the endoglycosidase PNGaseF led to identically deglycosylated haptoglobin in all samples 
(Fig. 1C). The glycosylation status of AGP was investigated by 2-D gel electorphoresis. AGP 
contains five highly sialylated complex-type N- glycans (24), and, due to its low pI narrow-
range IEF it can be analyzed readily without purification steps (25). The molecular masses of 
the AGP glycoforms were comparable in both control and patient samples. However, a shift 
to more basic pI values was observed in the patient sample (Fig. 1D). This shift was 
compatible with reduced terminal sialylation of the patient AGP. To determine whether 
reduced sialylation was limited to N-glycans, we also analyzed the sialylation of the serum O-
glycoprotein ApoCIII. The IEF of control and patient serum ApoCIII revealed the presence of 
unsialylated ApoCIII in the patient sample (Fig. 1E). 
A defect of terminal sialylation of both N- and O-glyans has been previously described in 
patients with deficiency of the COG complex (11, 26). COG deficiency is associated with 
delayed BFA-mediated collapse of the Golgi apparatus into the ER (20), which represents a 
simple test to assess a possible COG involvement in the underglycosylation of the present 
patient. Treatment of control and patient fibroblasts with BFA and monitoring of the Golgi 
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structure by 1,4 galactosyltransferase-I immunofluorescence confirmed the possibility of a 
COG deficiency, as shown by the BFA-resistant phenotype in the patient cells (Fig. 2).  
To detect possible mutations in COG genes, we first amplified the corresponding transcripts 
by RT-PCR. In this survey, we noticed an unexpectedly short cDNA besides the normal 
COG5 cDNA. Using various primer sets allowing the amplification of partial stretches of the 
COG5 mRNA, we localized the cause of the shorter transcript to a region of the COG5 gene 
encompassing exons 13 to 18 (Fig. 3A and B). Direct sequencing of both COG5 cDNAs 
revealed the skipping of exons 15 and 16 in the shorter transcript. Sequence analysis of the 
patient genomic DNA identified a homozygous mutation in the intronic region 15 bp 
upstream of exon 15 (c.1669-15T>C), which is presumably leading to the observed altered 
splicing. To exclude common single nucleotide polymorphisms, we screened 200 unrelated 
alleles using a MALDI-TOF-MS-based procedure for polymorphism genotyping (27). Fifty of 
these alleles were derived from samples of similar ethnical and geographical region to the 
patient’s family. None of the alleles analyzed carried the COG5 mutation c.1669-15T>C (data 
not shown). Haplotype analysis of the family validated our findings since the parents both 
carry the intronic mutation (Fig. 3C). The expression of the shorter transcript was calculated 
to create a loss of 58 amino acids (6.4 kDa) in the COG5 protein since the loss of exons 15 
and 16 does not lead to a frameshift during translation. To examine this finding, we analyzed 
the size and amount of the COG5 protein by Western blotting in control and patient 
fibroblasts. As shown in Fig. 3D, the low level of full length COG5 protein detected in the 
patient fibroblasts confirmed the disease-causing effect of the splicing mutation. However, no 
shorter protein was observed, suggesting that the truncated protein was unstable and prone to 
degradation. 
To address whether the detected COG5 mutation was uniquely responsible for the trafficking 
defect, we introduced a wildtype COG5 cDNA by lentivirus-mediated transfection in the 
patient fibroblasts. After confirming the stable expression of the wildtype COG5 construct in 
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the fibroblasts (data not shown), we treated the cells with BFA and monitored the collapse of 
the Golgi apparatus as done before. Whereas the patient cells transfected with a mock 
lentivirus construct showed the previously described delayed collapse of the Golgi apparatus, 
the patient cells expressing the normal COG5 cDNA showed the same rapid collapse of the 
Golgi apparatus as normal cells, thereby confirming the causality of the COG5 deficiency in 
the observed phenotype (Fig. 4). As a control, we also showed that expression of either a 
mock or a COG5 construct in normal fibroblasts did not significantly affect the speed of the 
collapse. 
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DISCUSSION 
The identification of forms of CDG caused by COG deficiency marked a new era in CDG 
pathogenesis, since these defects affect glycosylation indirectly through altered trafficking of 
glycosyltransferases. To date, deficiencies in the COG1, COG4, COG7 and COG8 subunits 
have been related to a form of CDG. The first case identified, namely COG7 deficiency, was 
described for two siblings who died in their first months of life (13). Subsequently identified 
COG7 patients were also severely affected so that it has been concluded as COG7 deficiency 
is mainly a lethal multisystemic disorder (28, 29). Two patients are known to be affected at 
the COG8 locus (15, 16). The clinical features were not as severe as those observed in COG7 
deficiency, but both COG8 patients were strongly retarded. They showed obvious 
neurological abnormalities and required hospitalization. Up to now, the COG1 patients and 
the recently published COG4 case have represented the group with the mildest clinical 
features (14, 17, 26, 30). However, the present case of COG5 deficiency was even milder, 
since her clinical status allowed her to live a regular life and to attend a college with 
therapeutic support. 
The moderate clinical outcome of the present patient might be explained by the rather mild 
glycosylation defect observed in the COG5-deficient cells, since only terminal sialylation was 
affected. This mild glycosylation phenotype yielded only minor changes in the IEF profile of 
serum transferrin (Fig. 1A), meaning that complementary tests, such as an ESI-MS analysis, 
were required to confirm the pathological nature of the finding. Considering the moderate 
clinical features of the COG5-deficient patient and the nearly normal transferrin IEF profile, 
we would recommend the application of secondary tests in similar putative cases of CDG. A 
similar weak glycosylation phenotype was also seen in COG5-depleted HeLa cells (31) and a 
mild phenotype was also noted in loss of COG5 function in D. melanogaster, which only 
affected spermatogenesis (32). In contrast, analysis of patient cells with COG1 and COG7 
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defects revealed that 1,4-linked galactose residues were also partially missing in addition to 
decreased terminal sialylation (17).  
 
COG subunits may each mediate interaction with different set of proteins, thus explaining 
varying severity of defects. Defect at a single subunit does not obligatorily destabilize the 
whole complex. Along this line, it has been shown that deficiency of the TRAPPC2 subunit of 
the TRAPP complex, another tethering factor, leads to a spondyloepiphyseal dysplasia tarda, a 
disease affecting the secretion of some extracellular matrix proteins (33). 
The intronic mutation in the COG5 allele is leading to partial skipping of exons 15 and 16 and 
sequence analysis of the shorter transcript suggested the expression of a truncated COG5 
protein in the patient cells, especially because the shorter transcript was more abundant.  
However, only the full length protein was detected upon Western blot analysis. We assume 
that the shorter COG5 protein is unstable and thus leading to its degradation.  
The description of additional cases of COG deficiency will eventually establish whether the 
severity of COG deficiency relates to the affected COG subunit or rather to the level of 
inactivation conferred by individual mutations irrespectively of the subunits themselves.  
Since the splicing mutation described here enabled the expression of full-size COG5 protein, 
yet to low levels, we would assume that other mutations may lead to more severe forms of 
COG5 deficiency. The identification of a novel mutation in the COG complex is important, 
since only eleven patients with defects in four of the subunits of the complex have been 
described so far. It emphasizes that probably all the subunits are essential for correct Golgi 
trafficking and glycosylation and it is likely that mutations in all subunits of the COG 
complex could be identified soon among untyped CDG cases. The present description of the 
COG5 defect in this patient calls for a revision of the concept that COG deficiencies represent 
rather severe forms of CDG. Accordingly, we would recommend testing for possible COG 
defects also among cases of mild neurological disorders.
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MATERIALS AND METHODS 
Glycosylation analysis of serum glycoproteins 
IEF of transferrin was performed as described (7) using Immobiline DryPlates (pH 4–7, GE 
Healthcare) and the Phast System (GE Healthcare). Two-dimensional SDS-PAGE for AGP 
analysis was carried out as described by Kleinert et al. (25). Transferrin was isolated from 
serum samples and analyzed with electrospray ionization mass spectrometry as reported (22). 
Antibodies and Western blotting 
Anti-haptoglobin was purchased from Rockland (Gilbertsville, PA, USA) and anti-ApoCIII 
from ANAWA (Wangen, CH). Anti-COG5 was a gift from Dr. D. Ungar (University of York, 
York, UK) and was used at a dilution of 1:100. Proteins were separated by SDS-PAGE and 
immunoblotted. Signals were detected using the ECL detection kit (Amersham Biosciences). 
Enzymatic deglycosylation of serum haptoglobin was performed using PNGase F (New 
England Biolabs). 
Sequencing and mutation analysis of COG5 gene 
Total RNA was isolated from fibroblasts using Qiagen RNeasy Kit (Qiagen Inc.). Reverse 
transcription was performed using QIAGEN OneStep RT-PCR Kit. Mutation screening of the 
COG genes COG1 to COG8 was carried out by fluorescent sequencing of cDNA-amplified 
PCR products on an ABI 3100 automated sequence detection system (Applied Biosystems). 
PCR conditions and primer sequences are available from the authors upon request. Genomic 
DNA was isolated from peripheral blood leukocytes using DNeasy Blood & Tissue Kit 
(Qiagen Inc.). For amplification of the COG5 cDNA region that was used to examine the 
skipping of exon 15 and 16, respectively, the following primers were used: 5'- 
GATTATGATCCAGAAAAGGCT -3' (forward) and 5'- GGATAATGACCCAGAAAAGTC 
-3' (reverse). These primers span the exons 13 – 18. For amplification of the genomic region 
that includes the mutation identified in this study, the following primers were used: 5’- 
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TAACATTCTCTTTGTCAGA -3’ (forward) and 5’- GCCAGAGTCAAAGACTGT -
3’(reverse). The exact PCR protocols are available on request. 
Single nucleotide polymorphism analysis 
The genomic DNA region containing the mutation was amplified using the forward and 
reverse primer pair 5'-TAACATTCTCTTTGTCAGA-3' (forward) and 5'-
GCCAGAGTCAAAGACTGT-3' (reverse). The PCR product was purified using the 
QIAquick PCR purification kit (Qiagen Inc.) and used as template for the allele-specific 
primer extension. The extension reaction was performed with the extension primer 5’-
TCATTCTGACACATTCTLTTTGAA-3’ containing a photocleavable linker. The exact PCR 
protocols are available on request. The extended product was purified using the genopure 
oligo kit (Bruker Daltonics) according to the manufacturer's instructions. The sample was 
transferred to an AnchorChip sample target (400 µm, Bruker Daltonics) preloaded with 3-
HPA matrix. After UV-cleavage of the linker, molecular masses of the extension products 
were determined with an Autoflex MALDI-TOF mass spectrometer (Bruker Daltonics) in the 
linear mode.  
Cell culture  
A punch biopsy of skin from the upper arm was taken from the index patient, minced and 
incubated in DMEM medium with 10% fetal calf serum, 0.5% penicillin and streptomycin 
(Invitrogen) at 37°C under 5% CO2. Primary fibroblasts cultures were obtained by expansion 
of fibroblast cells growing out of skin explants after 7-14 days. The fibroblasts were further 
cultured in DMEM with 10% fetal calf serum and 0.5% penicillin and streptomycin at 37°C. 
BFA assay and immunofluorescence microscopy 
Fibroblasts were grown over night on glass cover slips to about 60 % confluence. Medium 
was then changed with pre-warmed medium containing 2 g/ml of BFA (LC laboratories). 
The assay was stopped at different time points by fixing the cells with 3% paraformaldehyde. 
The cells were permeabilized with 0.1% saponin in PBS followed by immunostaining using a 
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mouse monoclonal antibody to the human 1,4 galactosyltransferase-I protein in a 1:50 
dilution (gift from Dr. E. G. Berger, University of Zurich, Switzerland). Anti-mouse Alexa 
Fluor-488 antibody was purchased from Molecular Probes (Invitrogen) and pictures were 
taken with a fluorescence microscope (Axiovert 200, Zeiss). 
Cloning of COG5 and transfection of fibroblasts 
The vector encoding COG5 cDNA was obtained from Open Biosystems (MHS1010-
97227871). The terminal 113 bp of COG5 missing in this construct were introduced as a 
BamHI-XbaI PCR fragment amplified from fibroblast cDNA with the following primer:  
5’-TTGGATCCTCCAGCTCAGGAAAACCTGATG-3' (forward, including a BamHI 
restriction site) and 5’-CGTCTAGAGGGTTAGCACAAAGTGGAGATG-3' (reverse, 
including a XbaI restriction site). The complete COG5 cDNA was then subcloned into 
pLenti6 vector (Invitrogen) using BamHI and SacII restriction sites. Transfection of 
fibroblasts using lentiviral vectors was carried out as described previously (35). 
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FIGURE LEGENDS 
 
Figure 1. Glycosylation of serum glycoproteins. A, IEF of transferrin from healthy control 
(H), patient (P) and PMM2 deficient patient (PMM2). The number of sialic acid residues is 
given on the left. B, Electrospray ionization mass spectrometry analysis of transferrin from 
healthy control (H) and patient (P). The deconvoluted mass spectra with the molecular masses 
(kDa) and the relative intensity are indicated. The fully glycosylated transferrin (tetrasialo) 
and the lighter trisialo-transferrin are marked with arrows. C, Western blot analysis of 
haptoglobin in healthy control (H), PMM2 deficient patient (PMM2) and patient (P), before (-
) and after (+) PNGaseF treatment. D, Narrow range 2-D gel electrophoresis of AGP from 
healthy control (H) and patient (P). Molecular weight (MW) and isoelectric point (pI) are 
indicated. E, IEF and immunoblotting of ApoCIII of healthy control (H) and patient (P). The 
number of sialic acid residues is marked at the left. 
 
Figure 2. Retrograde transport in BFA treated cells. Healthy control (H) and patient (P) 
fibroblast were treated with BFA for the indicated time. The Golgi apparatus was stained with 
1,4 galactosyltransferase-I antibody. The scale bar corresponds to 20 m. 
 
Figure 3. COG5 mutation analysis. A, Schematic representation of the COG5 gene 
organization surrounding the mutation. The positions of the primers used in the RT-PCR and 
of the mutation are indicated. B, RT-PCR analysis of mRNA isolated from healthy control 
(H) and patient (P) fibroblasts. The primers used span exons 13 to 18. The healthy control 
cDNA fragment is 557 bp-long. The RT-PCR product from the patient sample showed an 
additional, shorter fragment of 383 bp. The bp-marker is shown at the left. C, 
Electropherograms corresponding to the stretch of COG5 genomic DNA encompassing the 
c.1669-15T>C mutation as detected from healthy control DNA (H), patient DNA (P) and 
DNA from the parents of the patient. The mutation is indicated by an arrow. D, Steady-state 
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levels of the COG5 protein detected by Western blotting from healthy control (H) and patient 
(P) fibroblasts. -actin was used as loading control. 
 
Figure 4. Retrograde transport in fibroblast cells expressing a wildtype COG5 cDNA. 
Healthy control (squares) and patient (triangles) fibroblasts were lentivirally transduced with 
either a mock (opened) or a COG5 cDNA (closed) construct. The Golgi apparatus was stained 
with 1,4 galactosyltransferase-I antibody. For each time point 250 cells were counted and the 
values expressed in percents of cells with an ER-staining pattern. 
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ABBREVIATIONS 
AGP, 1-acid glycoprotein; ApoCIII, apolipoprotein CIII; BFA, brefeldin-A; CDG, 
congenital disorders of glycosylation; COG, conserved oligomeric Golgi; ER, endoplasmic 
reticulum; IEF, isoelectric focusing; PMM2, phosphomannomutase-2 
 
 
 
 
